A total of 3,577,860 doses of the Pfizer vaccine have arrived in Nigeria from the United States.
This is according to a statement released by the United States Mission in Nigeria on Thursday.
“The U.S. Mission in Nigeria is pleased to announce the arrival of 3,577,860 doses of Pfizer vaccine for the public health and benefit of the Nigerian people through COVAX, the worldwide initiative ensuring equitable access to COVID-19 vaccines,” the statement said.
“The U.S. shipment arrived at the Nnamdi Azikiwe International Airport in Abuja on October 14. The shipment will bring the total number of U.S.-bilaterally donated doses to Nigeria to over 7.5 million. The U.S. also contributed to the first multilateral donation of AstraZeneca vaccine in March 2021.
“Overall, COVAX has provided Nigeria with over 10 million doses to date.”
The mission noted that safe and effective vaccines remain the best tool to ending the pandemic.
“The United States has pledged to purchase and donate 1.1 billion COVID-19 vaccine doses worldwide, and to date has delivered more than 180 million doses to more than 100 countries,” the statement added.
US drugmaker Pfizer said Thursday it has formally requested emergency use authorization for its COVID-19 vaccine in children aged five to 11.
Children have been infected in greater numbers in the latest coronavirus wave driven by the Delta variant, and inoculating young people is seen as key to keeping schools open and helping end the pandemic.
In late September, Pfizer and BioNTech, which co-developed the vaccine, began submitting data to the Food and Drug Administration regulators for the highly anticipated authorization.
Pfizer tweeted early Thursday that the two companies had “officially submitted our request” to the FDA “for Emergency Use Authorization (EUA) of our #COVID19 vaccine in children 5 to <12.”
“We’re committed to working with the FDA with the ultimate goal of helping protect children against this serious public health threat,” Pfizer said.
Following the announcement White House Covid coordinator Jeff Zients told CNN that “I think we can all agree that getting a safe and effective vaccine for kids five to 11 is a really important next step in our fight against the virus.”
Children in the 5-11 age group received a two-dose regimen of 10 micrograms in the trial, compared with 30 micrograms for older age groups. The shots were given 21 days apart.
The FDA has previously said that once the formal submission was completed, the agency would complete its review “likely in a matter of weeks rather than months.”
The Pfizer-BioNTech vaccine has been granted full FDA approval for those age 16 and up.
The Federal Government on Monday said over 3.5 million doses of Pfizer vaccine are expected from the United States, as part of measures to ensure all Nigerians get vaccinated against the virus.
Briefing reporters in Abuja, Chairman of the Presidential Steering Committee (PSC) on COVID-19, Boss Mustapha, said notable progress is being made in the area of vaccines.
“Over 3.5 million doses of Pfizer are being expected from the US Government this month while about four million doses of AstraZeneca are being expected early next month,” he said.
“Nigeria will be receiving over one million doses of Johnson and Johnson (J&J) shipments on a monthly basis. The PSC is committed to accessing enough vaccines for the 70% eligible persons in the country in record time.”
Mustapha said the PSC has taken note of the challenges raised by travellers who visit the National International Travel Portal in compliance with travel protocols.
He lamented that some airport staff were not diligent in the discharge of their duties with respect to the quarantine procedure.
According to him, the PSC “has similarly noted with dismay, fraudulent activities perpetrated at our international airports by on-duty staff, who extort money out of those who equally wish to evade quarantine requirement.”
Mustapha, who is also the Secretary to the Government of the Federation, explained that the authorities are conducting the necessary investigations into various reports received.
He added, “On the United Kingdom advisory on COVID-19 vaccines and changes to international travel rules, the British High Commissioner to Nigeria has stated that the UK government, of course, supports the vaccination programme in the country with vaccines irrespective of where they were manufactured.
“They will, however, open up international travels using a standardised COVID-19 vaccination certification process, to allow for ease of travels from countries – Nigeria inclusive.”
The United States on Wednesday authorized the use of boosters of Pfizer’s Covid-19 vaccine for people aged over 65, as well as adults at high risk of severe disease and those in high-exposure jobs.
The announcement means a significant part of the population — amounting to tens of millions of Americans — are now eligible for a third shot six months after their second.
“Today’s action demonstrates that science and the currently available data continue to guide the FDA’s decision-making for COVID-19 vaccines during this pandemic,” said Janet Woodcock, acting head of the Food and Drug Administration, in a statement.
The decision was expected and came after an independent expert panel convened by the regulatory agency last week voted in favor of recommending the move.
The panel, however, rejected an initial plan by the White House to fully approve Pfizer boosters to everyone aged 16 and over, in what amounted to a rare rebuke of President Joe Biden’s administration.
The group of vaccinologists, infectious disease specialists and epidemiologists concluded that the benefit-risk balance differed for younger people, especially young males who are more susceptible to myocarditis.
– More boosters debated –
Pfizer Covid-19 boosters are currently being debated by a separate body of experts convened by the Centers for Disease Control and Prevention (CDC), which may recommend further specifics about recipients.
For example, if obesity is considered as putting a person “at high risk of severe Covid,” that definition would cover more than 42 percent of the US population aged over 20.
The CDC may also have to define which workplaces and other settings might lead to “frequent institutional or occupational exposure to SARS-CoV-2.”
For its part, the FDA indicated this would cover “health care workers, teachers and day care staff, grocery workers and those in homeless shelters or prisons, among others.”
The FDA’s emergency use authorization (EUA) applies to those aged 18 and up for the high risk of severe disease and high-exposure categories. It also only applies to Pfizer’s vaccine.
Recipients of Moderna and Johnson & Johnson, the other US-authorized vaccines, will now await news for when they, too, might become eligible for another shot.
A number of studies have shown two doses of Pfizer or Moderna, or a single shot of J&J, continue to confer high protection against severe outcomes — but this is slightly reduced for the elderly.
The World Health Organization has called for a moratorium on wealthy countries giving out boosters, while many countries — especially those in Africa — have barely begun their immunization campaigns.
The United States argues, however, it is possible to both help middle- and lower-income nations while also protecting its own vulnerable people.
On Wednesday, President Biden announced the United States would buy 500 million more Pfizer doses for the world, bringing its total contribution of the global supply to 1.1 billion.
Speaking to CNN on Sunday, top government scientist Anthony Fauci said that more research is needed to make a decision on whether a booster shot is warranted for the general public.
“As we said in the beginning, we would want to plan for the possibility of vaccinating all those who have gotten their initial vaccination with Pfizer,” Fauci said. “And it was always pending the evaluation of all of the totality of the data from the United States, from Israel, and any bit of data that we could get by the advisory committee to the FDA.”
Fauci added that the FDA panel decided against a third shoot for everybody aged 16 and over “in the proper deliberative process and they came up with a recommendation.”
President Joe Biden opened a Covid-19 summit of world leaders Wednesday with a promise to donate a “historic” extra 500 million vaccines to countries struggling to push back against the pandemic.
“This is an all-hands-on-deck crisis,” Biden said. “America will become the arsenal for vaccines as we were the arsenal for democracy in World War II.”
The pledge from Biden at the summit, held virtually from the White House, brings the total US commitment of donated vaccines to 1.1 billion — more than the rest of the world combined.
“The US has already shipped 160 million of these doses to 100 countries,” the White House said in a statement. “For every one shot we’ve put in an American arm to date, we are now donating three shots globally.”
The new tranche of half a billion vaccines will be from Pfizer and aimed at poorer countries.
Biden was also due to challenge world leaders to vaccinate 70 percent of every country by September 2022, the White House said.
In his opening remarks, he stressed that the surge of vaccines must only be donated, with no “political” strings attached — a veiled dig at China in particular.
The United States and other wealthy countries have been criticized by the World Health Organization for their plans to roll out booster shots for elderly and high-risk populations, while much of the world faces a severe shortage in doses.
But a senior US administration official told reporters that Washington is “proving that you can take care of your own, while helping others as well.”
On Tuesday, in his first speech to the UN as president, Biden told delegates that the United States had put more than $15 billion towards the global Covid response and shipped more than 160 million doses to other countries.
– 70 percent target –
Despite the development of safe and highly effective vaccines in record-breaking time, huge disparities exist between countries with ample supply and others that have barely begun their immunization campaign.
Just 3.6 percent of Africa’s eligible population has been inoculated — compared with an average of more than 60 percent in Western Europe.
The summit — technically held on the sidelines of the UN General Assembly — saw Biden and US Ambassador to the UN Linda Thomas-Greenfield hosting a wide variety of health and foreign leaders.
They included UN Secretary-General Antonio Guterres, World Health Organization chief Tedros Adhanom Ghebreyesus, and the heads of Britain, Canada, the European Union, Indonesia, and South Africa.
Washington will seek to rally the world around three goals, the administration official said.
These are: increasing vaccine supply; saving lives now by resolving the oxygen crisis and access to testing, medicine and therapeutics; and lastly improving future preparedness.
On vaccines, Biden will set an “ambitious target, which will require all countries to step up, so that every country, including low income and low middle income countries can achieve 70 percent vaccination before” next year’s UN General Assembly, the official said.
While the latest global coronavirus wave peaked in late August, the virus continues to spread rapidly, particularly in the United States, which is officially the worst-hit country.
Some 4.7 million have died since the outbreak began in China in December 2019, according to an AFP tally from official sources.
Pfizer and BioNTech on Monday said trial results showed their coronavirus vaccine was safe and produced a robust immune response in children aged five to 11, adding that they would seek regulatory approval shortly.
The vaccine would be administered at a lower dosage than for people over 12, they said.
“In participants five to 11 years of age, the vaccine was safe, well tolerated and showed robust neutralising antibody responses,” US giant Pfizer and its German partner said in a joint statement.
They plan to submit their data to regulatory bodies in the European Union, the United States and around the world “as soon as possible”.
The trial results are the first of their kind for children under 12, with a Moderna trial for six-11 year olds still ongoing.
Both the Pfizer and Moderna jabs are already being administered to adolescents over 12 and adults in countries around the globe.
Although children are considered less at risk of severe Covid, there are concerns that the highly contagious Delta variant could lead to more serious cases.
Innoculating children is also seen as key to keeping schools open and helping end the pandemic.
“We are eager to extend the protection afforded by the vaccine to this younger population,” said Pfizer CEO Albert Bourla, noting that “since July, paediatric cases of COVID-19 have risen by about 240 percent in the US”.
Kids in the 5-11 age trial group received a two-dose regimen of 10 microgrammes in the trial, compared with 30 microgrammes for older age groups, the companies said. The shots were given 21 days apart.
The 10 microgramme dose was “carefully selected as the preferred dose for safety, tolerability and immunogenicity” for that age group, the statement said.
– Under-5s before year-end – The side effects were “generally comparable to those observed in participants 16 to 25 years of age”, it added.
Among the most commonly reported side effects in the past have been pain and swelling at the injection site as well as headache, chills and fever.
Israel has already given special authorisation to vaccinate children aged 5-11 who are “at significant risk of serious illness or death” from Covid, using the Pfizer jab at the lower dosage.
Pfizer and BioNTech are also trialling their vaccine on infants aged six months to two years, and on children aged two to five.
The topline results for those trials are expected “as soon as” the fourth quarter of this year, the companies said.
All together, up to 4,500 children aged six months to 11 years have enrolled in the Pfizer-BioNTech trials in the US, Finland, Poland and Spain.
Like its Moderna rival, the Pfizer jab is based on novel mRNA technology that delivers genetic instructions to cells to build the coronavirus spike protein, in order to evoke antibodies when bodies encounter the real virus.
The Covid vaccine, which may now be marketed under its brand name Comirnaty, is the first to receive full approval.
Tens of millions of shots have already been administered under an emergency use authorization (EUA) that was granted on December 11, 2020.
The decision to award it approval was based on updated data from the drug’s clinical trial, including a longer duration of follow-up, with safety and effectiveness evaluated among more than 40,000 people.
The US military has previously announced it will mandate the vaccine as soon as it receives full approval, and a slew of private businesses and universities are expected to follow.
The vaccine remains available under emergency use authorization to children aged 12 to 15, but because it has now been fully approved, physicians may prescribe it to children under 12 if they believe it will be beneficial.
Israelis aged 40 and over will be able to receive coronavirus vaccine booster shots starting this weekend, Health Minister Nitzan Horowitz said Thursday, as the country battles a spike in infections.
Israel was one of the first countries to launch a vaccination drive in mid-December via an agreement with Pfizer to obtain millions of paid vaccine doses in exchange for sharing data on their effectiveness.
The inoculation campaign was hailed as a success story that helped drastically reduce infections in the country of nine million.
But cases have been rising due to the spread of the Delta variant among the unvaccinated and waning immunity in others.
To try and contain the spread, authorities last week began administrating a booster shot to those aged 50 and older, after starting a campaign for over-60s late last month.
Horowitz, who is among those who have received a third dose, tweeted Thursday that people aged 40 and over will be able to get a booster shot from Sunday.
“We have vaccines for everyone and now those 40 and older can receive a third dose,” he wrote. “The vaccine is effective. Let’s stop this Delta.”
Israel has recorded more than 970,000 coronavirus infections since the pandemic started early last year, and over 6,700 deaths.
More than 5.4 million people have received two doses of the vaccine, while 1.2 million have had a third jab.
Earlier this month, the World Health Organization called for a moratorium on Covid-19 vaccine booster shots to help ease the drastic inequity in dose distribution between rich and poor nations.
The first generation vaccine developed by BioNTech-Pfizer works against coronavirus variants such as the Delta strain and does not need to be modified for the moment, the chief executive of German company BioNTech said Monday.
“It is quite possible that in the next six to 12 months, further variants will emerge and that would require adaptation of the vaccine but it is at the moment not yet the case,” Ugur Sahin told journalists.
A decision to make a switch should be made only if it is clear that the vaccine failed to work or is only offering sub-par protection against the virus.
The fast-changing situation meant that getting the timing for the change right was also crucial.
“Making a decision at the moment might turn out to be wrong in three or six months if another variant is dominating. Therefore the timing of the decision must be appropriate,” he said.
Pfizer lifted its annual revenue and profit projections Wednesday on surging demand for Covid-19 vaccine doses as executives amplified their case for booster shots amid the latest wave of infections.
The two-shot inoculation accounted for more than 40 percent of Pfizer’s sales in the second quarter, boosting revenues sharply compared with the same three months of 2020.
Pfizer Chief Executive Albert Bourla said more than a billion doses of the vaccine have been delivered so far.
The US drugmaker, which has partnered with Germany’s BioNTech on the vaccine, now expects to deliver 2.1 billion doses this year, generating $33.5 billion in sales, topping the May forecast for $26 billion in sales on 1.6 billion doses.
Bourla said “the speed and efficiency of our efforts with BioNTech to help vaccinate the world against Covid-19 have been unprecedented.”
In the second quarter, the company logged profits of $5.6 billion, up 59 percent from the prior year on a 92 percent increase in revenues to $19 billion.
Recent commercial developments for the Pfizer-BioNTech vaccine venture include a May agreement with the European Union, a June deal with the United States for 500 million doses to donate to the poorest countries, and a letter of intent signed in July with the Biovac Institute to manufacture the vaccine in Africa.
The pre-tax profit margin on the Covid-19 vaccine was in the high-20 percent range, the same as the earlier forecast, the company said.
That has raised the ire of non-governmental organizations such as Public Citizen, which has accused Pfizer of “profiteering” on the pandemic and called on world leaders to launch a multi-billion dollar campaign to build vaccine manufacturing capacity and “vaccinate the world.”
But Pfizer, which has resisted efforts to roll back patent protections on vaccines, has defended its policies, saying it has priced the shots moderately in middle income countries and at cost for low-income countries.
Bourla also said he expects Pfizer to deliver one billion doses to middle-and-low income countries this year and another one billion in 2022.
The company expects to produce a total of three billion Covid-19 vaccines, meaning additional contracts could be announced this year.
– A third shot? – Much of the 90-minute conference call with Wall Street analysts focused on the prospect for additional vaccine-related revenue, notably from booster shots that Pfizer has argued will be needed to contain Covid-19.
Bourla has said he expects “durable demand” for Covid-19 vaccines, similar to that of the annual flu shot.
Pfizer has launched clinical studies on a possible third dose of the vaccine, and plans to submit data on the booster shot to the government next month.
The company’s presentation included charts showing a third jab boosting effectiveness against new variants, including fast-spreading Delta.
“What we have said for months is that we believe…. we will need a booster eight to 12 months from the second dose, and we have seen with the Delta that might be needed a little bit earlier for some parts of the population,” Bourla told analysts on a conference call.
US health officials have thus far been circumspect on the need for a third shot for the broad population, but officials are studying the need in immunocompromised people.
“Americans who have been fully vaccinated do not need a booster shot at this time,” according to a July 8 statement from the Food and Drug Administration and the Centers for Disease Control and Prevention.
“We are prepared for booster doses if and when the science demonstrates that they are needed,” the agencies said.
On Tuesday, the Centers for Disease Control and Prevention shifted course and directed vaccinated people to resume wearing masks indoors in high-risk parts of the United States.
Bourla suggested government’s response thus far on boosters reflects the normal process.
“We haven’t submitted the data yet, so I don’t think the FDA or CDC can speak because they have very different authority when they speak,” Bourla said.
Shares of Pfizer rose 2.9 percent to $43.31 in midday trading.
US drugmaker Pfizer on Wednesday confirmed that suspect doses of its coronavirus vaccine that were seized in Mexico and Poland were indeed fake, with doses going for as much as $1,000 a shot, according to US media.
At a clinic in Mexico some 80 people received bogus doses of the drug, which appeared to have been physically harmless, though offering no protection against the potentially deadly disease ravaging the country, a report in the Wall Street Journal said.
The vials were found in beer coolers and were initially identified by fabricated lot numbers and expiration dates, Mexican officials said.
The liquid in the confiscated vials in Poland was a cosmetic substance, thought to be anti-wrinkle cream, the company said.
“We are cognizant that in this type of environment — fueled by the ease and convenience of e-commerce and anonymity afforded by the internet — there will be an increase in the prevalence of fraud, counterfeit and other illicit activity as it relates to vaccines and treatments for Covid-19,” a Pfizer spokesperson told ABC News.
In February, health authorities in the northern Mexican state of Nuevo Leon warned about “clandestine” sales of “alleged Covid vaccines” and urged people not to take them.
In March, the World Health Organization also warned of “falsified” Pfizer vaccines found in Mexico and warned that the shots “may still be in circulation in the region.”
Pfizer tested the bogus vials and found they did not contain the two-shot vaccine it developed with BioNTech.
Lev Kubiak, Pfizer’s head of global security, said the desperate need and the shortfall in vaccines had led to the scams.
“We have a very limited supply, a supply that will increase as we ramp up and other companies enter the vaccine space. In the interim, there is a perfect opportunity for criminals,” he told the Wall Street Journal.
Mexico is also examining a shipment of 6,000 doses of what is claimed to be the Russian vaccine Sputnik that were seized on a private plane headed for Honduras last month, the newspaper said.